The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology

Autor: Gail P. Risbridger, Ashlee K. Clark, Laura H. Porter, Roxanne Toivanen, Andrew Bakshi, Natalie L. Lister, David Pook, Carmel J. Pezaro, Shahneen Sandhu, Shivakumar Keerthikumar, Rosalia Quezada Urban, Melissa Papargiris, Jenna Kraska, Heather B. Madsen, Hong Wang, Michelle G. Richards, Birunthi Niranjan, Samantha O’Dea, Linda Teng, William Wheelahan, Zhuoer Li, Nicholas Choo, John F. Ouyang, Heather Thorne, Lisa Devereux, Rodney J. Hicks, Shomik Sengupta, Laurence Harewood, Mahesh Iddawala, Arun A. Azad, Jeremy Goad, Jeremy Grummet, John Kourambas, Edmond M. Kwan, Daniel Moon, Declan G. Murphy, John Pedersen, David Clouston, Sam Norden, Andrew Ryan, Luc Furic, David L. Goode, Mark Frydenberg, Mitchell G. Lawrence, Renea A. Taylor

Publikováno v: Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)

The prognosis of castration-resistant prostate cancers remains dismal, but accurate preclinical models can lead to effective therapies. Here the Melbourne Urological Research Alliance establish prostate cancer patient-derived xenografts, use the tumo

Externí odkaz: https://doaj.org/article/72ce33db9321419ba5cb98782c40a1e1

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

Autor: Christopher J Sweeney, Andrew J Martin, Martin R Stockler, Stephen Begbie, Leanna Cheung, Kim N Chi, Simon Chowdhury, Mark Frydenberg, Lisa G Horvath, Anthony M Joshua, Nicola J Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A North, Francis Parnis, Wendy Parulekar, David W Pook, Martin Neil Reaume, Shahneen K Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott G Williams, Diana Winter, Sonia Yip, Alison Y Zhang, Robert R Zielinski, Ian D Davis, Ehtesham Abdi, Suzanne Allan, Patricia Bastick, Robert Blum, Karen Briscoe, Daniel Brungs, Sean Bydder, Bala Renuka Chittajallu, Michelle Cronk, Katharine Cuff, Anthony Dowling, Matthew George, Lisa Horvath, Elizabeth Hovey, Anthony Joshua, Narayan Karanth, Ganessan Kichenadasse, Laurence Krieger, Maitham Mathlum, Louise Nott, Zulfiquer Otty, David Pook, Shahneen Sandhu, Sanjeev Sewak, Amanda Stevanovic, Martin Stockler, Aneta Suder, Hsiang Tan, Javier Torres, Simon Troon, Craig Underhill, Andrew Weickhardt, Robert Zielinski, Tahir Abbas, Ghadeer Anan, Chris Booth, Holly Campbell, Kim Chi, Joseph Chin, Edmond Chouinard, Bryan Donnelly, Darrel Drachenberg, Amir Faghih, Antonio Finelli, Sebastien Hotte, Krista Noonan, Scott North, Mohammad Rassouli, Neil Reaume, Ricardo Rendon, Fred Saad, Evgeny Sadikov, Eric Vigneault, Pawel Zalewski, Patrick Morris, Miriam O'Connor, Paul Donnellan, Dearbhaile O'Donnell, Jim Edwards, Peter Fong, Simon Crabb, Omar Khan, Vincent Khoo, Graham Macdonald, Heather Payne, Angus Robinson, Jonathon Shamash, John Staffurth, Carys Thomas

Publikováno v: The Lancet Oncology. 24:323-334

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c3cc53ef2d430b7a9cb81427e074aeef
https://doi.org/10.1016/s1470-2045(23)00063-3

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

Autor: Stephen Begbie, Wendy R. Parulekar, Scott North, Francis Parnis, Alvin Tan, David Pook, John McCaffrey, Xanthi Coskinas, Thean Hsiang Tan, M. Neil Reaume, Scott Williams, Francisco E. Vera-Badillo, Alastair Thomson, Emily Tu, Shahneen Sandhu, Alison Yan Zhang, Andrew J. Martin, Anthony M. Joshua, Lisa G. Horvath, Nicola Jane Lawrence, Margaret McJannett, Wendy Hague, Martin R. Stockler, Ian D. Davis, Christopher Sweeney, Robert Zielinski, Ray McDermott, Mark Frydenberg, Simon Chowdhury, Gavin Marx, Kim N. Chi, Sonia Yip

Publikováno v: European Urology. 80:275-279

Men who initially present with localized prostate cancer and later develop metachronous metastases have a better prognosis than men with de novo metastatic disease and often have a low burden of disease on conventional imaging. Some have disease amen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c89e5cd5827a78e84a6994cb6b6b50
https://doi.org/10.1016/j.eururo.2021.05.016

Androgen receptor enhancer amplification in matched patient‐derived xenografts of primary and castrate‐resistant prostate cancer

Autor: David Pook, Mural investigators, Andrew Bakshi, Ashlee K. Clark, Renea A. Taylor, David L Goode, David Clouston, John Kourambas, Gail P. Risbridger, Laura H Porter, Mitchell G. Lawrence

Publikováno v: The Journal of Pathology. 254:121-134

Amplifications of the androgen receptor (AR) occur in up to 80% of men with castration-resistant prostate cancer (CRPC). Recent studies highlighted that these amplifications not only span the AR gene but usually encompass a distal enhancer. This repr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c8eda21e82d810499b72a74e4d9f949
https://doi.org/10.1002/path.5652

Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer

Autor: Tilman Todenhöfer, Lisa G. Horvath, Andrew Mant, Maria Docanto, Edmond M. Kwan, Nicole Ng, Stefano Mangiola, Kate L. Mahon, Ian D. Davis, Sarah Q. To, David Pook, Lisa Jane K. Graham, Arun Azad, Heidi Fettke, Carmel Pezaro, Phillip Parente, Patricia Bukczynska, Eva Segelov

Publikováno v: European Urology Focus. 7:63-70

The treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC) has evolved significantly in recent years. Identifying predictive and/or prognostic biomarkers in the context of this rapidly expanding therapeutic armamentarium remai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb31148479814a82d3266e533c52e3e
https://doi.org/10.1016/j.euf.2019.04.020